NEW YORK (GenomeWeb) – CombiMatrix today announced that the New York State Department of Health has approved the firm's CombiSNP Array for Prenatal Diagnosis.

The CombiSNP Array uses chromosomal microarray analysis of chorionic villi and amniocentesis samples to detect chromosomal imbalances not detected by karyotyping.

"The prenatal diagnostic test we offer is important both as a first-tier test and as a tool physicians utilize to confirm the increasing number of positive non-invasive prenatal screening results," CombiMatrix CEO Mark McDonough said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.